葛根素注射液联合氟桂利嗪治疗脑动脉硬化症的临床研究

目的探讨葛根素注射液联合盐酸氟桂利嗪胶囊治疗脑动脉硬化症的临床疗效。方法选取2017年3月—2018年2月郑州市第九人民医院收治的脑动脉硬化症患者104例为研究对象,按照随机数字表法将患者分为对照组和治疗组,每组各52例。对照组口服盐酸氟桂利嗪胶囊,5 mg/次,2次/d。治疗组在对照组治疗的基础上静脉滴注葛根素注射液,0.2 g加入到5%葡萄糖注射液250 mL中充分稀释,0.2 g/次,1次/d。两组患者均连续治疗4周。观察两组患者的临床疗效,比较两组治疗前后的脑血流动力学水平和血管内皮功能。结果治疗后,对照组和治疗组患者的总有效率分别为78.85%、92.31%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者的血管阻力(RI)、血管搏动指数(PI)水平显著降低,脑内动脉收缩期血流(MCAVs)、椎动脉收缩期血流(VAVs)水平显著升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗后,治疗组患者的RI、PI、MCAVs和VAVs改善水平明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者血清一氧化氮(NO)水平显著升高,内皮素-1(ET-1)、促血管生成素-2(Ang-2)水平显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗后,治疗组血管内皮功能明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论葛根素注射液联合盐酸氟桂利嗪胶囊治疗脑动脉硬化症的疗效确切,能够改善脑血流动力学和血管内皮功能,具有一定的临床推广应用价值。

Clinical study on Puerarin Injection combined with flunarizine in treatment of cerebral arteriosclerosis

Objective To investigate the clinical efficacy of Puerarin Injection combined with Flunarizine Hydrochloride Capsules in the treatment of cerebral arteriosclerosis. Methods Patients (104 cases) with cerebral arteriosclerosis in Ninth People''s Hospital of Zhengzhou from March 2017 to February 2018 were randomly divided into control and treatment groups, and each group had 52 cases. Patients in the control group were po administered with Flunarizine Hydrochloride Capsules, 5 mg/time, twice daily. Patients in the treatment group were iv administered with Puerarin Injection on the basis of the control group, 0.2 g added to glucose injection 250 mL, 0.2 g/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the cerebral hemodynamic levels, vascular endothelial function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 78.85% and 92.31%, respectively, and there was difference between two groups (P<0.05). After treatment, RI and PI levels in two groups were significantly decreased, but MCAVs and VAVs levels in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, RI, PI, MCAVs, and VAVs levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum NO levels in two groups were significantly increased, but the ET-1, Ang-2 levels were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the vascular endothelial function in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Puerarin Injection combined with Flunarizine Hydrochloride Capsules has significant clinical effect in treatment of cerebral arteriosclerosis, can improve the cerebral hemodynamic levels and vascular endothelial function, which has a certain clinical application value.